Abbott and Sanofi are partnering to integrate their glucose sensing and insulin delivery technologies, with ambitions to simplify how people with diabetes manage their condition.
The two companies are working on tools that combine Abbott’s FreeStyle Libre technology with Sanofi’s insulin dosing data. FreeStyle Libre is the most-used sensor-based glucose monitoring system in the world, reading glucose levels through a sensor worn on the back of the upper arm and eliminating the need for finger-prick tests.
The partners hope that the collaboration will enable the development of future smart pens, insulin titration apps and cloud software.
Data will be shared between Abbott’s FreeStyle Libre app and cloud software and Sanofi’s connected insulin pens, apps and cloud software. The data sharing will enable diabetics and their doctors to make better-informed treatment decisions.
Sanofi is currently working to develop its share of the technology to be used as part of the partnership, which will be compatible with the FreeStyle Libre system and its corresponding digital health tools.
Sanofi Global Diabetes and Cardiovascular Franchise senior vice president Gustavo Pesquin said: “This strategic relationship with Abbott is representative of the next evolution of our commitment for better diabetes care by incorporating digital tools into the daily life of people living with diabetes.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“By partnering with Abbott, we are a step closer to realizing our connected ecosystem, which would help improve control and the quality of life decision cycle for patients through individualized glycemic management of diabetes.”
The two companies aim to bring their new technologies to diabetic customers within the next few years, pending regulatory approval.
Abbott Diabetes Care senior vice president Jared Watkin said: “As the global leader in continuous glucose monitoring, we see a significant opportunity to impact the health of millions of people living with diabetes by developing new tools and connectivity with Sanofi, a leader in the insulin space.”
“Diabetes can be overwhelming as it is an information-rich condition with various streams of data from multiple devices. Building a digital ecosystem around FreeStyle Libre simplifies the user experience by consolidating how people get their data – both through offering Abbott′s digital health tools and by working with other diabetes and technology leaders.”